# EDGAR Filing Document

**Accession Number:** 0001612630
**File Stem:** 0001612630-25-000021
**Filing Date:** 2025-8
**Character Count:** 47434
**Document Hash:** 847bfe7a6d8f04492f9a66b18eae3c26
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001612630-25-000021.hdr.sgml**: 20250807

**ACCESSION NUMBER**: 0001612630-25-000021

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 38

**CONFORMED PERIOD OF REPORT**: 20250807

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250807

**DATE AS OF CHANGE**: 20250807

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** JOINT Corp
- **CENTRAL INDEX KEY:** 0001612630
- **STANDARD INDUSTRIAL CLASSIFICATION:** PATENT OWNERS & LESSORS [6794]
- **ORGANIZATION NAME:** 05 Real Estate & Construction
- **EIN:** 900544160
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36724
- **FILM NUMBER:** 251193996

**BUSINESS ADDRESS:**
- **STREET 1:** 16767 N PERIMETER DRIVE
- **STREET 2:** SUITE 110
- **CITY:** SCOTTSDALE
- **STATE:** AZ
- **ZIP:** 85260
- **BUSINESS PHONE:** 480 245 5960

**MAIL ADDRESS:**
- **STREET 1:** 16767 N PERIMETER DRIVE
- **STREET 2:** SUITE 110
- **CITY:** SCOTTSDALE
- **STATE:** AZ
- **ZIP:** 85260

?xml version='1.0' encoding='ASCII'? jynt-20250807

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 7, 2025

**The Joint Corp.**

(Exact Name of Registrant as Specified in Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-36724** | **90-0544160** |
| (State or other jurisdiction | (Commission File Number) | (IRS Employer |
| of incorporation) | | Identification No.) |

---

**16767 N. Perimeter Drive, Suite 110**

**Scottsdale, Arizona 85260**

(Address of principal executive offices) (Zip Code)

**(480) 245-5960**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.001 | JYNT | The NASDAQ Capital Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 §CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

------

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 2.02. Results of Operations and Financial Condition.**

On August 7, 2025, The Joint Corp. (the "Company") issued a press release announcing its financial results for the quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information furnished in this Item 2.02 and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such a filing.

**Item 7.01. Regulation FD Disclosure.**

The Company is posting an earnings presentation to its website at https://ir.thejoint.com/. A copy of the earnings presentation is being furnished herewith as Exhibit 99.2. The Company will use the earnings presentation during its earnings conference call on August 7, 2025 and also may use the earnings presentation from time to time in conversations with analysts, investors and others.

The information furnished in this Item 7.01 and Exhibit 99.2 shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing.

The information contained in Exhibit 99.2 is summary information that is intended to be considered in the context of the Company's filings with the SEC. The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.

**Item 9.01. Financial Statements and Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) *Exhibits.*

---

| | |
|:---|:---|
| <u>Exhibit Number</u> | <u>Exhibits</u> |
| <u>[99.1](a25-08x07jyntq2x25release.htm)</u> | <u>[Press Release, dated August 7, 2025](a25-08x07jyntq2x25release.htm)</u> |
| <u>[99.2](a25-08x07jyntq22025final.htm)</u> | <u>[The Joint Corp. Earnings Presentation, dated August 7, 2025](a25-08x07jyntq22025final.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| | | | **THE JOINT CORP.** |
| Date: | August 7, 2025 | By: | */s/ Sanjiv Razdan* |
|  |  |  | Sanjiv Razdan |
|  |  |  | President and Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![logoa.jpg](logoa.jpg)

**The Joint Corp. Reports Second Quarter 2025 Financial Results**

*- Refranchised 37 clinics; Franchises now represent 92% of the portfolio -* 

*- Acquired rights to the Northwest regional developer territory -* 

**SCOTTSDALE, Ariz., August 7, 2025** – The Joint Corp. (NASDAQ: JYNT), a national operator, manager, and franchisor of chiropractic clinics, posted operating highlights and limited financial information for the quarter ended June 30, 2025. The following figures represent continuing operations unless otherwise stated.

**Q2 2025 Financial Highlights summary** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Grew revenue to $13.3 million, up 5% compared to Q2 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Increased system-wide sales<sup>1</sup> 2.6% to $129.6 million.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Reported comp sales<sup>2</sup> of 1.4%.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Reported net income from consolidated operations of $93,000, compared to a net loss of $3.6 million in the second quarter of 2024. Reported net loss from continuing operations of $990,000, compared to a net loss of $1.7 million in the second quarter of 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA for consolidated operations increased 52% to $3.2 million, while Adjusted EBITDA from continuing operations improved to $88,000, compared to Adjusted EBITDA loss of $380,000 in the second quarter of 2024.

**Q2 2025 Operating Highlights** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Sold 13 franchise licenses in Q2 2025, compared to seven sold in Q2 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Refranchised 37 clinics for $11.2 million.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Acquired the rights to the Northwest regional developer (RD) territory for $2.8 million.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Opened seven and closed six franchised clinics.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Closed three company-owned or managed clinics.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Clinic count was 967 as of June 30, 2025 with 885 franchised and 82 corporate clinics.

"At the beginning of 2025, we laid out our multi-year strategy to strengthen our core, reignite growth and improve both clinic and company level profitability, and we're making progress across these initiatives," said President and Chief Executive Officer of The Joint Corp. Sanjiv Razdan. "We are increasing momentum in becoming a pure play franchisor with 92% franchised clinics in our portfolio at quarter end. By allocating funds to both RD buybacks and our recently established share repurchase program, we are leveraging capital to increase shareholder value.

"While the macro environment remains dynamic, we are focusing on actions within our control: Fueling our growth flywheel and reducing costs. We have strengthened our leadership in franchise development, finance, legal, operations, and patient experience. To drive long-term system wide sales, we are enhancing our brand campaign, pivoting from a broad-based wellness positioning to the sharper concept

<sup>1</sup> System-wide sales include revenues at all clinics, whether operated or managed by the company or by franchisees. While franchised sales are not recorded as revenues by the company, management believes the information is important in understanding the company's financial performance, because these revenues are the basis on which the company calculates and records royalty fees and are indicative of the financial health of the franchisee base.

 <sup>2</sup> Comp sales include the revenues from both company-owned or managed clinics and franchised clinics that in each case have been open at least 13 full months and exclude any clinics that have closed.

------

**&nbsp;&nbsp;&nbsp;&nbsp;**

of pain relief. We will shift our marketing spend to an earlier point in the sales funnel and invest in our marketing infrastructure to improve search performance. We launched our mobile app, with the goal of enriching our patients' experience and extending their lifetime value. Additionally, we plan to continue implementing nominal price increases to optimize holistic pricing while balancing affordability and patient value. When we place patients at the heart of everything we do, the business grows, profitability follows and everyone wins."

**Financial Results for First Quarter Ended June 30, 2025 Compared to June 30, 2024**

Revenue increased 5% to $13.3 million, compared to $12.6 million in the second quarter of 2024. Cost of revenue was $2.8 million for both periods.

Selling and marketing expenses increased 1% to $3.5 million, mainly driven by the digital marketing transformation efforts. Depreciation and amortization expenses increased 18%, due to depreciation expenses related to internal use software enhancements and developments, including the launch of the new mobile app. General and administrative expenses decreased 1% to $7.7 million, driven by progress on corporate cost reduction efforts related to refranchising.

Income tax expense was $11,000, consistent with the second quarter of 2024. Consolidated net income was $93,000, compared to a net loss of $3.6 million in the second quarter of 2024. Net loss from continuing operations was $990,000, compared to a net loss of $1.7 million in the second quarter of 2024. Consolidated EPS was $0.01 per diluted share, compared to a net loss of $0.24 per basic share in the second quarter of 2024.

Adjusted EBITDA from consolidated operations increased 52% to $3.2 million, while Adjusted EBITDA from continuing operations improved to $88,000, compared to Adjusted EBITDA loss of $380,000 in the second quarter of 2024.

**Balance Sheet and Cash Flow**

Unrestricted cash was $29.8 million at June 30, 2025, compared to $25.1 million at December 31, 2024. Additionally, the company maintains a line of credit with JP Morgan Chase, which grants immediate access to $20 million through February 2027.

**2025 Guidance** 

In light of softer sales trends coupled with macro headwinds, the company is taking a balanced view of the remainder of the year and is revising 2025 guidance as follows.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• System-wide sales are now expected to range from $530 million to $550 million, versus prior guidance of $550 million to $570 million.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Comp sales for all clinics open 13 months or more are now expected to be in the low-single digit range versus prior guidance of mid-single digit growth.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Consolidated Adjusted EBITDA has been increased to be in the range of $10.8 million to $11.8 million versus prior guidance of $10.0 million to $11.5 million.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• New franchised clinic openings, excluding the impact of refranchised clinics, are now expected to be in the range of 30 to 35, compared to 57 in 2024.

**Conference Call** 

The Joint Corp. management will host a conference call at 5:00 p.m. ET on Thursday, August 7, 2025, after the market close. Stockholders and interested participants may listen to a live broadcast of the conference call by dialing 1-(833) 630-0823 or (412) 317-1831 and ask to be joined into the 'The Joint' call approximately 15 minutes prior to the start time.

The live webcast of the call with accompanying slide presentation can be accessed in the IR events section https://ir.thejoint.com/events and available for approximately one year. An audio archive can be

------

**&nbsp;&nbsp;&nbsp;&nbsp;**

accessed for one week by dialing (877) 344-7529 or (412) 317-0088 and entering conference ID 5002166.

**Comments to Financial Results**

As announced on July 30, 2025, we intend to restate our previously issued financial statements included in our 2024 Annual Report Form 10-K for the fiscal year ended December 31, 2024 and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 due to material errors identified by management related to the non-cash impairment recorded for clinics held for sale within discontinued operations. Specifically, the Company determined the original valuation methodology for certain assets held for sale was not consistent with generally accepted accounting principles, and adjustments were made to accurately present the Company's financial statements. From an income statement standpoint, the adjustments resulted in a decrease in net loss for fiscal 2024 and an increase in net income for the first quarter of 2025. These adjustments are not expected to have any impact on Adjusted EBITDA for fiscal 2024 or the first quarter of 2025. The effect on the balance sheet will be an increase of the carrying value of assets held for sale. Due to the necessary change in prior financial statements, as of the date of this filing, we are providing limited financial statements, including the income statement and Adjusted EBITDA for the three months ended June 30, 2025 and 2024, and the unrestricted cash and cash balance as of June 30, 2025.

**Commonly Discussed Performance Metrics**

This release includes a presentation of commonly discussed performance metrics. System-wide sales include revenues at all clinics, whether operated by the company or by franchisees. While franchised sales are not recorded as revenues by the company, management believes the information is important in understanding the company's financial performance, because these sales are the basis on which the company calculates and records royalty fees and are indicative of the financial health of the franchisee base. Comp sales include the revenues from both company-owned or managed clinics and franchised clinics that in each case have been open at least 13 full months and exclude any clinics that have closed.

**Non-GAAP Financial Information** 

This release also includes a presentation of non-GAAP financial measures. EBITDA and Adjusted EBITDA are presented because they are important measures used by management to assess financial performance, as management believes they provide a more transparent view of the company's underlying operating performance and operating trends. Reconciliation of historical net income/(loss) to EBITDA and Adjusted EBITDA is presented in the table below. The company defines EBITDA as net income/(loss) before net interest, tax expense, depreciation, and amortization expenses. The company defines Adjusted EBITDA as EBITDA before acquisition-related expenses (which includes contract termination costs associated with reacquired regional developer rights), net (gain)/loss on disposition or impairment, stock-based compensation expenses, costs related to restatement filings, restructuring costs, litigation expenses (consisting of legal and related fees for specific proceedings that arise outside of the ordinary course of our business) and other income related to employee retention credits.

EBITDA and Adjusted EBITDA do not represent and should not be considered alternatives to net income or cash flows from operations, as determined by accounting principles generally accepted in the United States, or GAAP. While EBITDA and Adjusted EBITDA are used as measures of financial performance and the ability to meet debt service requirements, they are not necessarily comparable to other similarly titled captions of other companies due to potential inconsistencies in the methods of calculation. EBITDA and Adjusted EBITDA should be reviewed in conjunction with the company's financial statements filed with the SEC.

Please refer to the reconciliations of non-GAAP financial measures to their GAAP equivalents located at the end of this release. This release includes forward-looking guidance for certain non-GAAP financial measures, including Adjusted EBITDA. These measures will differ from net income (loss), determined in accordance with GAAP, in ways similar to those described in the reconciliations at the end of this release.

------

**&nbsp;&nbsp;&nbsp;&nbsp;**

We are not able to provide, without unreasonable effort, guidance for net income (loss), determined in accordance with GAAP, or a reconciliation of guidance for Adjusted EBITDA to the most directly comparable GAAP measure because the Company is not able to predict with reasonable certainty the amount or nature of all items that will be included in net income (loss).

**Forward-Looking Statements**

This press release contains statements about future events and expectations that constitute forward-looking statements. Forward-looking statements are based on our beliefs, assumptions and expectations of industry trends, our future financial and operating performance and our growth plans, taking into account the information currently available to us. These statements are not statements of historical fact. Words such as, "anticipates," "believes," "continues," "estimates," "expects," "goal," "objectives," "intends," "may," "opportunity," "plans," "potential," "near-term," "long-term," "projections," "assumptions," "projects," "guidance," "forecasts," "outlook," "target," "trends," "should," "could," "would," "will," and similar expressions are intended to identify such forward-looking statements. Specific forward-looking statements made in this press release include, among others, that in 2025, our multi-year strategy to strengthen our core, reignite growth and improve both clinic and company level profitability and our belief that we are making progress across these initiatives; our belief that we are increasing momentum in becoming a pure play franchisor; our belief that by allocating funds to both RD buybacks and our recently established share repurchase program, we are leveraging capital to increase shareholder value; our focus on actions within our control: fueling our growth flywheel and reducing costs; our efforts to drive long-term system wide sales, by enhancing our brand campaign, pivoting from a broad-based wellness positioning to the sharper concept of pain relief; our plan to shift our marketing spend to an earlier point in the sales funnel and invest in our marketing infrastructure to improve search performance; our goal of enriching our patients' experience and extending their lifetime value through the launch of our mobile app; our plan to continue implementing nominal price increases to optimize holistic pricing while balancing affordability and patient value; our belief that when we place patients at the heart of everything we do, the business grows, profitability follows and everyone wins; and our revised 2025 guidance for system-wide sales, comp sales for all clinics open 13 months or more, Consolidated Adjusted EBITDA, and new franchised clinic openings, excluding the impact of refranchised clinics. Forward-looking statements involve risks and uncertainties that may cause our actual results to differ materially from the expectations of future results we express or imply in any forward-looking statements, and you should not place undue reliance on such statements. Factors that could contribute to these differences include, but are not limited to, our inability to identify and recruit enough qualified chiropractors and other personnel to staff our clinics, due in part to the nationwide labor shortage and an increase in operating expenses due to measures we may need to take to address such shortage; inflation, leading to increased labor costs and interest rates, as well as changes to import tariffs, may lead to reduced discretionary spending, all of which may negatively impact our business; our failure to profitably operate company-owned or managed clinics; our failure to refranchise as planned; short-selling strategies and negative opinions posted on the internet, which could drive down the market price of our common stock and result in class action lawsuits; our failure to remediate future material weaknesses in our internal control over financial reporting, which could negatively impact our ability to accurately report our financial results, prevent fraud, or maintain investor confidence; and other factors described in our filings with the SEC, including in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 14, 2025 and subsequent filings with the SEC. We qualify any forward-looking statements entirely by these cautionary factors. We assume no obligation to update or revise any forward-looking statements for any reason or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless expressed as such, and should only be viewed as historical data.

**About The Joint Corp. (NASDAQ: JYNT)** 

------

**&nbsp;&nbsp;&nbsp;&nbsp;**

The Joint Corp. (NASDAQ: JYNT) revolutionized access to chiropractic care when it introduced its retail healthcare business model in 2010. Today, it is the nation's largest operator, manager and franchisor of chiropractic clinics through The Joint Chiropractic network. The company is making quality care convenient and affordable, while eliminating the need for insurance, for millions of patients seeking pain relief and ongoing wellness. Headquartered in Scottsdale and with over 950 locations nationwide and more than 14 million patient visits annually, The Joint Chiropractic is a key leader in the chiropractic industry. The brand is consistently named to *Franchise Times'* annual "Top 400" and "Fast & Serious" list of 40 smartest growing brands. *Entrepreneur* named The Joint "No. 1 in Chiropractic Services," and is regularly ranked on the publication's "Franchise 500," the "Fastest-Growing Franchises," the "Best of the Best" lists, as well as its "Top Franchise for Veterans" and "Top Brands for Multi-Unit Owners." *SUCCESS* named the company as one of the "Top 50 Franchises" in 2024. The Joint Chiropractic is an innovative force, where healthcare meets retail. For more information, visit www.joint.com. To learn about franchise opportunities, visit www.thejointfranchise.com.

**Business Structure**

The Joint Corp. is a franchisor of clinics and an operator of clinics in certain states. In Arkansas, California, Colorado, District of Columbia, Florida, Illinois, Kansas, Kentucky, Maryland, Michigan, Minnesota, New Jersey, New York, North Carolina, Oregon, Pennsylvania, Tennessee, Washington, and West Virginia, The Joint Corp. and its franchisees provide management services to affiliated professional chiropractic practices.

**Media Contact:** 

Margie Wojciechowski, The Joint Corp., margie.wojciechowski@thejoint.com

**Investor Contact:** 

Kirsten Chapman, Alliance Advisors IR, (415) 433-3777, thejoint@allianceadvisors.com

**– Financial Tables Follow –** 

------

**&nbsp;&nbsp;&nbsp;&nbsp;**

**THE JOINT CORP.** 

**CONSOLIDATED INCOME STATEMENTS**

**(unaudited)**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>June 30,** | **Three Months Ended<br>June 30,** |
| | **2025** | **2024** |
| Revenues: |  |  |
| &nbsp;&nbsp;&nbsp;Royalty fees | $8133122 | $7846328 |
| &nbsp;&nbsp;&nbsp;Franchise fees | 768100 | 719103 |
| &nbsp;&nbsp;&nbsp;Advertising fund revenue | 2332695 | 2240839 |
| &nbsp;&nbsp;&nbsp;Software fees | 1481661 | 1415036 |
| &nbsp;&nbsp;&nbsp;Other revenues | 554692 | 388730 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total revenues | 13270270 | 12610036 |
| Cost of revenues: |  |  |
| &nbsp;&nbsp;&nbsp;Franchise and regional development cost of revenues | 2350613 | 2458186 |
| &nbsp;&nbsp;&nbsp;IT cost of revenues | 421994 | 354203 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total cost of revenues | 2772607 | 2812389 |
| Selling and marketing expenses | 3483844 | 3440391 |
| Depreciation and amortization | 402295 | 342454 |
| General and administrative expenses | 7745251 | 7793465 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total selling, general and administrative expenses | 11631390 | 11576310 |
| Net loss on disposition or impairment | 4440 | 662 |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss from operations | (1138167) | (1779325) |
| Other income, net | 159922 | 80471 |
| &nbsp;&nbsp;&nbsp;&nbsp;Loss before income tax expense | (978245) | (1698854) |
| Income tax expense | 11390 | 11169 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net loss from continuing operations | (989635) | (1710023) |
| Discontinued operations: |  |  |
| Income (loss) from discontinued operations before income tax expense | 1183199 | (1719222) |
| Income tax expense from discontinued operations | 100201 | 167153 |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) from discontinued operations | 1082998 | (1886375) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income (loss) | $93363 | $(3596398) |
| Net loss from continuing operations per common share: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | $(0.06) | $(0.11) |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | $(0.06) | $(0.11) |
| Net income (loss) from discontinued operations per common share: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | $0.07 | $(0.13) |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | $0.07 | $(0.12) |
| Net income (loss) per common share: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Basic | $0.01 | $(0.24) |
| &nbsp;&nbsp;&nbsp;&nbsp;Diluted | $0.01 | $(0.24) |
| Basic weighted average shares | 15326317 | 14950082 |
| Diluted weighted average shares | 15400408 | 15206238 |

---

------

**&nbsp;&nbsp;&nbsp;&nbsp;**

**THE JOINT CORP.**

**CONSOLIDATED RECONCILIATION FROM GAAP TO NON-GAAP**

**(unaudited)**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Three Months Ended June 30,** |
|  | **2025** | **2025** | **2025** | **2024** | **2024** | **2024** |
|  | **from Continuing Operations** | **from Discontinued Operations** | **Net Operations** | **from Continuing Operations** | **from Discontinued Operations** | **Net Operations** |
| &nbsp;&nbsp;**Non-GAAP Financial Data:** |  |  |  |  |  |  |
| &nbsp;&nbsp;(Loss) income | $(989635) | $1082998 | $93363 | $(1710023) | $(1886375) | $(3596398) |
| &nbsp;&nbsp;Net (interest) expense | (159922) |  | (159922) | (80471) | 561 | (79910) |
| &nbsp;&nbsp;Depreciation and amortization expense | 402295 | 17120 | 419415 | 342454 | 1181359 | 1523813 |
| &nbsp;&nbsp;Income tax expense | 11390 | 100201 | 111591 | 11169 | 167153 | 178322 |
| &nbsp;&nbsp;EBITDA | (735872) | 1200319 | 464447 | (1436871) | (537302) | (1974173) |
| &nbsp;&nbsp;Stock compensation expense | 330988 |  | 330988 | 552065 |  | 552065 |
| &nbsp;&nbsp;Acquisition-related expenses |  |  |  | 478710 |  | 478710 |
| &nbsp;&nbsp;Net loss on disposition or impairment | 4440 | 1752494 | 1756934 | 662 | 1434658 | 1435320 |
| &nbsp;&nbsp;Restructuring costs | 488493 | 198331 | 686824 | 25000 | 119240 | 144240 |
| &nbsp;&nbsp;Litigation expenses |  |  |  |  | 1490000 | 1490000 |
| &nbsp;&nbsp;Adjusted EBITDA | $88049 | $3151144 | $3239193 | $(380434) | $2506596 | $2126162 |

---

## Exhibit 99.2

![](a25-08x07jyntq22025final001.jpg)

NASDAQ: JYNT \|© 2025 The Joint Corp. All Rights Reserved. Q2 2025 Financial Results As of June 30, 2025, reported August 7, 2025 1

------

![](a25-08x07jyntq22025final002.jpg)

NASDAQ: JYNT \|© 2025 The Joint Corp. All Rights Reserved. Safe Harbor Statements Certain statements contained in this presentation are "forward-looking statements." We have tried to identify these forward-looking statements by using words such as "may," "might," " will," "expect," "anticipate,'' "'believe," "could," " intend," "plan," "estimate," "should," "if," "project," and similar expressions. All statements other than statements of historical facts contained in this presentation, including statements regarding our mission, our strategic plan, our growth strategies, our vision, our market growth opportunity, our multi-year phased approach, our refranchising plans, our efforts to drive revenue growth, our 2025 guidance, prospects, plans, objectives of management and expected market growth and potential are forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events. However, these forward-looking statements are subject to risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to be materially different from our expectations and projections. Some of these risks, uncertainties and other factors are set forth in this presentation and in other documents we file with the United States Securities and Exchange Commission (the "SEC"). Given these risks and uncertainties, readers are cautioned not to place undue reliance on our forward-looking statements. Projections and other forward-looking statements included in this presentation have been prepared based on assumptions, which we believe to be reasonable, but not in accordance with U.S. Generally Accepted Accounting Principals ("GAAP") or any guidelines of the SEC. Actual results may vary, perhaps materially. You are strongly cautioned not to place undue reliance on such projections and other forward-looking statements. All subsequent written and oral forward-looking statements attributable us or to persons acting on our behalf are expressly qualified in their entirety by these cautionary statements. Except as required by federal securities laws, we disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Any such forward-looking statements, whether made in this presentation or elsewhere, should be considered in the context of the various disclosures made by us about our businesses including, without limitation, the risk factors discussed above. Accounting Adjustments Related to the Consolidation of the Operations of the PCs In those states which require a licensed Doctor of Chiropractic to own the entity that offers chiropractic services, the Company enters into a management agreement with a professional corporation (PC) licensed in that state to provide chiropractic services. To increase transparency into operating results and to align with accounting rules, the Company will now consolidate the full operations of the PC. This will result in increases to our revenue and G&A expenses by an identical amount and would have no impact on our bottom line except in instances when the PC has sold treatment packages and wellness plans. Revenue from these packages and plans will now be deferred and will be recognized when patients use their visits. The Company has previously consolidated its clinic operations in Non-PC states such as Arizona and New Mexico, and the deferred revenue around packages and plans in those states was already reflected in its financial statements. Therefore, these adjustments are isolated to the managed clinics in PC states. These adjustments will have no impact on cash flow. Comments to Financial Results As announced on July 30, 2025, we intend to restate our previously issued financial statements for our 2024 Annual Report Form 10-K and our Quarter Ended Q1'2025 Form 10-Q due to material errors identified by management related to the non-cash impairment recorded for clinics held for sale within discontinued operations. Specifically, the Company determined the original valuation methodology for certain assets held for sale applied was not consistent with generally accepted accounting principles, and adjustments were made to accurately present the Company's financial statements. From an income statement standpoint, the adjustments resulted in decrease in net loss for 2024 and an increase in net income for the first quarter of 2025. These adjustments are not expected to have any impact on Adjusted EBITDA for 2024 or the first quarter of 2025. The effect on the balance sheet will be an increase of the carrying value of assets held for sale. Due to the necessary change in prior financial statements, as of the date of this filing, we are providing limited financial statements, including the income statement and Adjusted EBITDA for the three months ended June 30, 2025 and 2024, respectively, and the unrestricted cash and cash balance as of June 30, 2025. Business Structure The Joint Corp. is a franchisor of clinics and an operator of clinics in certain states. In Arkansas, California, Colorado, District of Columbia, Florida, Illinois, Kansas, Kentucky, Maryland, Massachusetts, Michigan, Minnesota, New Jersey, New York, North Carolina, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Washington, West Virginia and Wyoming, The Joint Corp. and its franchisees provide management services to affiliated professional chiropractic practices. 2

------

![](a25-08x07jyntq22025final003.jpg)

NASDAQ: JYNT \|© 2025 The Joint Corp. All Rights Reserved. Sanjiv Razdan CEO, President and Director 3

------

![](a25-08x07jyntq22025final004.jpg)

NASDAQ: JYNT \|© 2025 The Joint Corp. All Rights Reserved. Our mission is to improve quality of life through routine and affordable chiropractic care. 4 Our vision is to build America's most accessible health and wellness services company.

------

![](a25-08x07jyntq22025final005.jpg)

NASDAQ: JYNT \|© 2025 The Joint Corp. All Rights Reserved. On Our Way to Becoming a Pure Play Franchisor 37 clinics refranchised • 31 clinics in Arizona and New Mexico • 5 clinics in Kansas City • 1 clinic in California • Actively engaged in refranchising the balance of the corporate portfolio 5

------

![](a25-08x07jyntq22025final006.jpg)

NASDAQ: JYNT \|© 2025 The Joint Corp. All Rights Reserved. Strengthen Brand Awareness & Digital Marketing 6 Sharpening marketing communications to pain relief from general wellness • 80% of new patients cite aches and pains as a reason for coming to The Joint. • More relevant creative educates prospects how to get back to doing what they love • SEO optimization to address changes in search behavior

------

![](a25-08x07jyntq22025final007.jpg)

NASDAQ: JYNT \|© 2025 The Joint Corp. All Rights Reserved. Initiated Dynamic Revenue Management 7 Optimize holistic pricing while balancing affordability and patient value • More frequent, smaller price increases than past • Walk-in pricing taken in Dec. 2024; Kickstart plans started in July 2025 • Will keep exploring holistic pricing opportunities in the balance of the year

------

![](a25-08x07jyntq22025final008.jpg)

NASDAQ: JYNT \|© 2025 The Joint Corp. All Rights Reserved. Upgrading Patient-facing Technology 8 Extending the lifetime value of our patients • Launched MVP in July • 10% active patients using app in August • Working on app 2.0, including gamification

------

![](a25-08x07jyntq22025final009.jpg)

NASDAQ: JYNT \|© 2025 The Joint Corp. All Rights Reserved. Scott Bowman Chief Financial Officer 9

------

![](a25-08x07jyntq22025final010.jpg)

NASDAQ: JYNT \|© 2025 The Joint Corp. All Rights Reserved. +52% Q2 2025 consolidated Adj. EBITA increase over Q2 2024 +1.4% Q2 2025 comp sales2 +2.6% Q2 2025 system-wide sales1 10 1 System-wide sales include revenues at all clinics, whether operated or managed by the company or by franchisees. While franchised sales are not recorded as revenues by the company, management believes the information is important in understanding the company's financial performance, because these revenues are the basis on which the company calculates and records royalty fees and are indica iv of the financial health of the franchisee base. \| 2 Comp sales include only the sales from clinics that have been open at least 13 full months and exclude any clinics that have permanently closed.

------

![](a25-08x07jyntq22025final011.jpg)

NASDAQ: JYNT \|© 2025 The Joint Corp. All Rights Reserved. 12 26 82 175 242 265 309 352 394 453 515 610 712 800 842 885 4 47 61 47 48 60 64 96 126 135 125 82 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Q2 2025 TOTAL CLINICS OPEN Franchised Company-owned and managed Reduced Regional Developer management to 52% of the clinics Increased Franchised Clinics to 92% of Portfolio 370 399 442 513 312 246 579 706 838 935 967 11 967

------

![](a25-08x07jyntq22025final012.jpg)

NASDAQ: JYNT \|© 2025 The Joint Corp. All Rights Reserved. 1 Due to rounding, numbers may not add up precisely to the totals. \| 2 The results of the corporate clinic segment are reported in from discontinued operations and the franchised clinics in continued operations \| 3 Reconciliation of Adjusted EBITDA to GAAP earnings is included in the Appendix. Q2 2025 as of Jun. 30, 2025 $ in M 1 3 mo.s 6/30/25 3 mo.s 6/30/24 Differences Revenue $13.3 $12.6 $0.7 5% Cost of revenues 2.8 2.8 0.0 (1)% Sales and marketing 3.5 3.4 0.1 1% Depreciation and amortization 0.4 0.3 0.1 18% G&A 7.7 7.8 (0.1) (1)% Operating loss (1.1) (1.8) 0.7 36% Other income 0.2 0.1 0.1 NA Income tax expense 0.0 0.0 0.0 NA Net loss from continuing operations 2 (1.0) (1.7) 0.7 42% Net income / (loss) from discontinued operations 2 1.1 (1.9) 3.0 NA Consolidated net income / (loss) 0.1 (3.6) 3.7 NA Adjusted EBITDA from continuing operations 3 0.1 (0.4) 0.5 NA Adjusted EBITDA from discontinued operations 3 3.1 2.5 0.6 NA Consolidated Adjusted EBITDA 3 3.2 2.1 1.1 52% 12

------

![](a25-08x07jyntq22025final013.jpg)

NASDAQ: JYNT \|© 2025 The Joint Corp. All Rights Reserved. Stock repurchase plan: • Authorized for up to $5M of outstanding common stock • Plan authorized through June 2027 1 JPMorgan Chase LOC provides immediate access to $20M through February 2027. Strong Liquidity $ in Ms 6/30/25 12/31/24 Unrestricted cash $29.8 $25.1 Restricted cash $1.2 $0.9 Available JP Morgan Chase LOC1 $20.0 $20.0 13

------

![](a25-08x07jyntq22025final014.jpg)

NASDAQ: JYNT \|© 2025 The Joint Corp. All Rights Reserved. Revising 2025 Guidance 14 $ in M 2024 Actual Prior 2025 Low Guidance Prior 2025 High Guidance Current 2025 Low Guidance Current 2025 High Guidance System-wide sales 1 $530.3 $550 $570 $530 $550 Comp sales for all clinics open 13 months or more 2 4% Mid-single digits Low-single digits Consolidated Adjusted EBTIDA 3 $11.4 $10.0 $11.5 $10.8 $11.8 New franchised clinic openings excluding the impact of refranchised clinics 57 30 40 30 35 1 System-wide sales include revenues at all clinics, whether operated or managed by the company or by franchisees. While franchised sales are not recorded as revenues by the company, management believes the information is important in understanding the company's financial performance, because these revenues are the basis on which the company calculates and records royalty fees and are indicative of the financial health of the franchisee base. \| 2 Comp sales include only the sales from clinics that have been open at least 13 full months and exclude any clinics that have permanently closed.

------

![](a25-08x07jyntq22025final015.jpg)

NASDAQ: JYNT \|© 2025 The Joint Corp. All Rights Reserved. Sanjiv Razdan CEO, President and Director 15

------

![](a25-08x07jyntq22025final016.jpg)

NASDAQ: JYNT \|© 2025 The Joint Corp. All Rights Reserved. Strengthen Clinic Economics & Reignite Growth 16 Excel in Patient Experience Turbo Charge Sales & Profits Rapidly Grow Clinic Network Build People Capability & Culture Innovate & Broaden Relevance OUR PATIENTS

------

![](a25-08x07jyntq22025final017.jpg)

NASDAQ: JYNT \|© 2025 The Joint Corp. All Rights Reserved. 17 Sandi Karrmann Director Chris Grandpre Director

------

![](a25-08x07jyntq22025final018.jpg)

NASDAQ: JYNT \|© 2025 The Joint Corp. All Rights Reserved. 18 Net New Clinic Openings Adjusted EBITDA Comp Sales System-wide Sales Committed to Driving Success

------

![](a25-08x07jyntq22025final019.jpg)

NASDAQ: JYNT \|© 2025 The Joint Corp. All Rights Reserved. Performance Metrics and Non-GAAP Measures 19 This presentation includes commonly discussed performance metrics. System-wide sales include revenues at all clinics, whether operated by the company or by franchisees. While franchised sales are not recorded as revenues by the company, management believes the information is important in understanding the company's financial performance, because these sales are the basis on which the company calculates and records royalty fees and are indicative of the financial health of the franchisee base. Comp sales include the revenues from both company-owned or managed clinics and franchised clinics that in each case have been open at least 13 full months and exclude any clinics that have closed. This presentation includes non-GAAP financial measures. EBITDA and Adjusted EBITDA are presented because they are important measures used by management to assess financial performance, as management believes they provide a more transparent view of the company's underlying operating performance and operating trends. Reconciliation of historical net income/(loss) to EBITDA and Adjusted EBITDA is presented in the table below. The company defines EBITDA as net income/(loss) before net interest, tax expense, depreciation, and amortization expenses. The company defines Adjusted EBITDA as EBITDA before acquisition-related expenses (which includes contract termination costs associated with reacquired regional developer rights), net (gain)/loss on disposition or impairment, stock-based compensation expenses, costs related to restatement filings, restructuring costs, litigation expenses (consisting of legal and related fees for specific proceedings that arise outside of the ordinary course of our business) and other income related to employee retention credits. EBITDA and Adjusted EBITDA do not represent and should not be considered alternatives to net income or cash flows from operations, as determined by accounting principles generally accepted in the United States, or GAAP. While EBITDA and Adjusted EBITDA are used as measures of financial performance and the ability to meet debt service requirements, they are not necessarily comparable to other similarly titled captions of other companies due to potential inconsistencies in the methods of calculation. EBITDA and Adjusted EBITDA should be reviewed in conjunction with the company's financial statements filed with the SEC. Please refer to the reconciliations of non-GAAP financial measures to their GAAP equivalents located in this presentation. This presentation includes forward- looking guidance for certain non-GAAP financial measures, including Adjusted EBITDA. These measures will differ from net income (loss), determined in accordance with GAAP, in ways similar to those described in the reconciliations at the end of this release. We are not able to provide, without unreasonable effort, guidance for net income (loss), determined in accordance with GAAP, or a reconciliation of guidance for Adjusted EBITDA to the most directly comparable GAAP measure because the Company is not able to predict with reasonable certainty the amount or nature of all items that will be included in net income (loss).

------

![](a25-08x07jyntq22025final020.jpg)

NASDAQ: JYNT \|© 2025 The Joint Corp. All Rights Reserved. GAAP – Non-GAAP Reconciliation Quarterly Continuing Operations 20

------

![](a25-08x07jyntq22025final021.jpg)

NASDAQ: JYNT \|© 2025 The Joint Corp. All Rights Reserved. GAAP – Non-GAAP Reconciliation Quarterly Discontinued Operations 21

------

![](a25-08x07jyntq22025final022.jpg)

NASDAQ: JYNT \|© 2025 The Joint Corp. All Rights Reserved. GAAP – Non-GAAP Reconciliation Quarterly Consolidated Operations 22

------

![](a25-08x07jyntq22025final023.jpg)

scott.bowman@thejoint.com Scott Bowman, CFO scott.bowman@thejoint.com The Joint Corp. \| 16767 N. Perimeter Dr., Suite 110, Scottsdale, AZ 85260 \| (480) 245-5960 https://www.facebook.com/thejointchiro https://twitter.com/thejointchiro https://www.youtube.com/thejointcorp https://www.facebook.com/thejointchiro @thejointchiro https://twitter.com/thejointchiro @thejointchiro https://www.youtube.com/thejointcorp @thejointcorp sanjiv.razdan@thejoint.com Sanjiv Razdan, President & CEO sanjiv.razdan@thejoint.com The Joint Corp. \| 16767 N. Perimeter Dr., Suite 110, Scottsdale, AZ 85260 \| (480) 245-5960 thejointinvestors@allianceadvisors.com Kirsten Chapman, LHA Investor Relations thejointinvestors@allianceadvisors.com Alliance Advisors Investor Relations \| 800 Third Ave, 17th Floor \| New York, NY 10022\| (415) 433-3777 NASDAQ: JYNT \|© 2025 The Joint Corp. All Rights Reserved. 23

------